From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms

JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease

(2014) J. Li et al.   BLOOD

CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis

(2014) E. Rumi et al.   BLOOD

Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms

(2014) P. Lundberg et al.   BLOOD

Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms

(2013) E. Rumi et al.   BLOOD

JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia

(2013) C. M. Hobbs et al.   BLOOD

Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia

(2013) G. Rotunno et al.   BLOOD

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes

(2013) E. Rumi et al.   BLOOD

The genetic basis of myelodysplasia and its clinical relevance

(2013) M. Cazzola et al.   BLOOD

Mutations and prognosis in primary myelofibrosis

(2013) A M Vannucchi et al.   LEUKEMIA

Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2

(2013) J. Nangalia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms

(2013) Thorsten Klampfl et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tryptophan at the transmembrane-cytosolic junction modulates thrombopoietin receptor dimerization and activation

(2013) J.-P. Defour et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Megakaryocytes Contribute to the Bone Marrow-Matrix Environment by Expressing Fibronectin, Type IV Collagen, and Laminin

(2013) Alessandro Malara et al.   STEM CELLS

Megakaryocyte pathology and bone marrow fibrosis: the lysyl oxidase connection

(2012) N. Papadantonakis et al.   BLOOD

Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis

(2012) Lambert Busque et al.   NATURE GENETICS

Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations

(2011) F. Passamonti et al.   BLOOD

Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression

(2011) T. Klampfl et al.   BLOOD

p53 Lesions in Leukemic Transformation

(2011) Ashot Harutyunyan et al.   NEW ENGLAND JOURNAL OF MEDICINE

In Vitro Megakaryocyte Differentiation and Proplatelet Formation in Ph-Negative Classical Myeloproliferative Neoplasms: Distinct Patterns in the Different Clinical Phenotypes

(2011) Alessandra Balduini et al.   PLoS One

The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms

(2010) A. V. Jones et al.   BLOOD

Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

(2010) Thomas Ernst et al.   NATURE GENETICS

Somatic Mutations ofIDH1andIDH2in the Leukemic Transformation of Myeloproliferative Neoplasms

(2010) Anthony Green et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis

(2009) L. Malcovati et al.   BLOOD

Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms

(2009) F. H. Grand et al.   BLOOD

Mutations of ASXL1 gene in myeloproliferative neoplasms

(2009) N Carbuccia et al.   LEUKEMIA

A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms

(2009) Damla Olcaydu et al.   NATURE GENETICS

JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms

(2009) Amy V Jones et al.   NATURE GENETICS

Mutation inTET2in Myeloid Cancers

(2009) François Delhommeau et al.   NEW ENGLAND JOURNAL OF MEDICINE

MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort

(2008) P. A. Beer et al.   BLOOD

Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice

(2007) R. Tiedt et al.   BLOOD